FDA expands Pfizer’s HYMPAVZI approval
Broadening access for children & patients with inhibitor-complicated hemophilia
Broadening access for children & patients with inhibitor-complicated hemophilia
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Nearly 1.43 crore families in West Bengal to benefit as India’s flagship health assurance scheme achieves full national coverage across all States and Union Territories
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Subscribe To Our Newsletter & Stay Updated